

PCT





WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: WO 98/50387
C07D 487/22, A61K 51/00, 41/00, 51/04, 51/10 // (C07D 487/22, 257:00, 209:00, 209:00, 209:00, 209:00)		(43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: PCT/CA98/00468		(74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Suite 2200, Box 11560, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).
(22) International Filing Date: 6 May 1998 (06.05.98)		(81) Designated States: AU, CA, CN, CZ, FI, HU, IL, JP, KR, MX, NO, NZ, PL, VN, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(30) Priority Data: 08/852,494 7 May 1997 (07.05.97) US		Published <i>With international search report.</i>
(71) Applicants: QLT PHOTOTHERAPEUTICS, INC. [CA/CA]; 520 West 6th Avenue, Vancouver, British Columbia V5Z 4H5 (CA). THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA).		
(72) Inventors: STERNBERG, Ethan; 3837 West 4th Avenue, Vancouver, British Columbia V6R 1P8 (CA). DOLPHIN, David; 4464 West 12th Avenue, Vancouver, British Columbia V6R 1P8 (CA). LEVY, Julia, G.; #601 - 1490 Pennyfarthing Drive, Vancouver, British Columbia V6J 4Z3 (CA). RICHTER, Anna, M.; PHI - 5775 Toronto Road, Vancouver, British Columbia V6T 1X4 (CA). HUNT, David, W., C.; 886 Habgood Street, White Rock, British Columbia V4B 4W3 (CA). ASHOK, Jain; #209 - 2150 Brunswick Street, Vancouver, British Columbia V5T 3L5 (CA).		

(54) Title: ETHYLENE GLYCOL ESTERS OF MONOHYDROBENZOPORPHYRIN DERIVATIVES AS PHOTOACTIVE AGENTS



(57) Abstract

New compounds useful in photodynamic therapy are of formula (1) or (2), (3) or (4) and the metallated and/or labeled and/or conjugated forms thereof wherein each R<sup>1</sup> is independently alkyl(1-6C); each n is independently an integer of 0-6; and R<sup>2</sup> is vinyl or a derivative form thereof.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LT	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## ETHYLENE GLYCOL ESTERS OF MONOHYDROBENZOPORPHYRIN DERIVATIVES AS PHOTOACTIVE AGENTS

Technical Field

The invention relates to compounds useful in photodynamic therapy (PDT) 5 and related applications. In particular, it concerns ethylene glycol esters of monohydrobenzoporphyrins.

Background Art

Photodynamic therapy (PDT) generally involves the administration of 10 compounds that are capable of absorbing light, typically in the visible range, but also in the near ultraviolet, followed by irradiation of locations in the subject for which a toxic or inhibitory effect is desired. PDT was initially developed using hematoporphyrin and related compounds in the treatment of tumors, as it appeared that these compounds would "home" to locations containing rapidly dividing cells. 15 The tumor could then be irradiated with light absorbed by the hematoporphyrin and destruction of the surrounding tissue resulted. PDT has since been shown to be useful for treatment of atherosclerotic plaques, restenosis, infections in the blood stream, rheumatoid arthritis, psoriasis and in the treatment of ocular conditions not necessarily limited to tumors.

20 U.S. Patent No. 5,171,749 and patents issuing on related applications, U.S. Patents Nos. 5,283,255; 5,399,583; 4,883,790; 4,920,143; and 5,095,030; all of which are incorporated herein by reference, describe and claim a class of photoactive compounds useful in PDT designated the monohydrobenzoporphyrins, or "BPDs." This class is obtained by Diels-Alder reaction of a mono- or disubstituted alkyne with 25 protoporphyrin-IX and the resultant compounds can further be isomerized, reduced, and/or derivatized to obtain a large class of BPDs. As disclosed in these patents, a particularly useful subclass of this group results from hydrolysis or partial hydrolysis of the ester groups of the 2-carboxyethyl side-chains on rings C and D. Esterification as protection of these groups during the Diels-Alder reaction results in initial products 30 which contain 2-carbalkoxyethyl groups. It was found that facile hydrolysis of these esters could readily be conducted, leaving any carbalkoxy groups associated with the

- 2 -


Diels-Alder product obtained from a dicarbalkoxyalkyne virtually completely unhydrolyzed. This resulted in four species of compounds, BPD-MA, BPD-MB, BPD-DA and BPD-DB as depicted in Figure 1; this figure taken from U.S. Patent No. 5,171,749. In this depiction, R<sup>1</sup> and R<sup>2</sup> are carbalkoxy groups, typically carbomethoxy or carboethoxy, and R is alkyl (1-6C).

- 5 BPD-MA was found to have particularly useful properties for PDT and is currently in clinical development. However, there remains a need for additional specific forms of photoactive agents which expand the repertoire of photoactive compounds for the variety of indications to which PDT is applied, as noted above.
- 10 10 The present invention provides compounds in which rings C and D contain ethylene glycol esters of the carboxyalkyl substituents. These compounds have pharmacokinetic properties which are advantageous in certain instances where PDT is employed.

15 Disclosure of the Invention

The compounds of the invention are useful new additions to the repertoire of compounds that find application in photodynamic therapy and related methodologies that employ photoactive compounds. The presence of ethylene glycol esters in these molecules provides them with characteristics that permit expansion of the scope of 20 conditions under which such photoactive compounds are employed and fine tuning of the treatment.


Thus, in one aspect, the invention is directed to compounds of the formula



and the metallated and/or labeled and or conjugated forms thereof

wherein R<sup>1</sup> is alkyl (1-6C), preferably methyl, n is an integer of 0-6, preferably 2, and R<sup>2</sup> is vinyl or a derivative thereof, preferably vinyl.

The invention also is directed to compounds of the formula



5

and the metallated and/or labeled and or conjugated forms thereof wherein R<sup>1</sup>, n, and R<sup>2</sup> are defined as described above. These analogs are derived from protoporphyrin III and protoporphyrin XIII respectively, in a manner similar to that in which the compounds of formulas 1 and 2 are derived from protoporphyrin IX. The invention 10 also includes isomers of the various forms of formulas 1-4 which result from the unarranged Diels-Alder condensation products (i.e. the 1,4-diene) as described in US Patent 4,883,790 incorporated herein by reference.

In other aspects, the invention related to methods of diagnosis and treatment using the compounds of formula 1, 2, 3 or 4 or their 1,4-diene isomers or mixtures 15 thereof.

#### Brief Description of the Drawings

Figure 1 shows the compounds of the prior art, BPD-MA, BPD-MB, BPD-DA and BPD-DB.

20 Figure 2 shows the kinetics of uptake of B-EA6 by L1210 cells.

Figure 3 shows the kinetics of release of B-EA6 by L1210 cells.

Figure 4 shows a graphic depiction of the pharmacokinetics of B-EA6 *in vivo*.

Figure 5 shows a comparison of the kinetics of uptake of B-EA6 by normal splenocytes and L1210 cells.

Figure 6 shows the time course of PDT using B-EA6 in mice as compared to mice treated with BPD-MA and BPD-MB.

5       Figure 7 shows the effect of B-EA6 on microvasculature in mice.

Figure 8 shows a comparison of the spectra in plasma of BPD-MA and B-EA6.

Figures 9A and 9B show the cytotoxic effect of photodynamic treatment using A-EA6 in comparison with BPD-MA in L1210 cells and in dendritic cells.

10      Figure 10 shows the comparative effects of A-EA6 and BPD-MA in decreasing the surface expression of MHC I receptors.

Figure 11 shows the effect of photodynamic therapy using A-EA6 and BPD-MA on stress and mitogenic pathway kinases in HL60 cells.

15      Figure 12 shows the comparative effect of PDT using A-EA6 and BPD-MA on caspase activation in HL60 cells.

Figure 13 shows the comparative effect of PDT using A-EA6 and BPD-MA on DNA fragmentation in HL60 cells.

#### Modes of Carrying Out the Invention

20      The compounds of the invention are related to those disclosed in the BPD patents cited above, but differ in that they contain esters of ethylene glycol in the substituents on rings C and D. These compounds can be prepared by simple hydrolysis of the carbalkoxyalkyl or carbalkoxyl substituents and reesterification of the resulting carboxyl groups in the C and D rings of the benzoporphyrins, or can be 25 obtained directly by transesterification.

It will be noted that compounds 1 and 2 are individual species of the genus, described in the above-referenced U.S. patents, obtained through a process which comprises a Diels-Alder reaction with protoporphyrin IX. Compounds 3 and 4 are prepared in a completely analogous manner but using protoporphyrin III or 30 protoporphyrin XIII as substrates for the Diels-Alder reaction. Since protoporphyrin IX is not symmetric with respect to the A and B rings, two possible products result

depending on whether the Diels-Alder addition occurs in the A or B ring. On the other hand, protoporphyrins III and XIII are symmetric with respect to these rings, and therefore only one product results in each case regardless of the site of addition.

In the compounds of the invention, R<sup>2</sup> is preferably vinyl, but may also be a derivative thereof. The vinyl group in ring A or B is readily derivatized to other embodiments of R<sup>2</sup> by addition or oxidation. The addition or oxidation products can be further substituted if the added substituents are functional as leaving groups, for example, -Br may be substituted by -OH, -OR", -NH<sub>2</sub>, -NHR", or -NR<sub>2</sub>", etc., where R" is a hydrocarbon radical. For instance, one of the added substituents may be 5 hydrogen and the other halo, hydroxy, lower alkoxy, amino, or an amide, sulphydryl or an organosulfide or an additional hydrogen. The compounds of the invention include various groups as R<sup>2</sup> including substituents which provide additional porphyrin or porphyrin-related ring systems.

Thus, R<sup>2</sup> may be vinyl, -CHOR', -CHO, -COOR', -CH(OR')CH<sub>3</sub>, -CH(OR')CH<sub>2</sub>OR', -CH(SR')CH<sub>3</sub>, -CH(NR')<sub>2</sub>CH<sub>3</sub>, -CH(CN)CH<sub>3</sub>, -CH(COOR')CH<sub>3</sub>, -CH(OOCR')CH<sub>3</sub>, -CH(NR'COR')CH<sub>3</sub>, -CH(CONR')<sub>2</sub>CH<sub>3</sub>, -CH(halo)CH<sub>3</sub>, or -CH(halo)CH<sub>2</sub>(halo) wherein R' is H, or a hydrocarbon radical (1-6C) optionally substituted with a heteroatom substituent or wherein R<sup>2</sup> is an organic group of less than 12C resulting from direct or indirect derivatization of the vinyl group, or wherein 10 R<sup>2</sup> is a group containing 1-3 tetrapyrrole-type nuclei.

As used herein, the term "alkyl" refers to a saturated straight or branched chain hydrocarbon which may, if it contains a sufficient number of carbon atoms, be cyclic or contain a cyclic portion. Typical examples are methyl, ethyl, t-butyl, cyclohexyl, and the like.

25 A "hydrocarbon radical" refers to a monovalent substituent containing only carbon and hydrogen which may be straight or branched chain, saturated or unsaturated, aromatic or nonaromatic or both, and cyclic or noncyclic. Thus, a hydrocarbon radical of 1-10C could include cyclopentylethyl, 2-pentenyl, 3-butynyl, 2,4-dimethylhexyl, and the like.

30 In some embodiments of the invention, the hydrocarbon radical may be substituted with a heteroatom-containing substituent. Such substituents include -OR,

- 6 -

-NR<sub>2</sub>, -SR, -COOR, -CONR<sub>2</sub>, -OOCR, -NRCOR, -SOR, -SO<sub>2</sub>R, -SO<sub>2</sub>R, halo, -CN, and the like, wherein R is H or alkyl (1-6C). Cyclic amines include pyridyl, pyrimidyl, thiazolyl, quinolyl, and so forth. Thus, they may include single ring or fused ring systems and may contain additional heteroatoms.

5 It will be noted that the compounds of the invention contain at least one chiral center and thus may exist in various stereoisomeric forms. If desired, such stereoisomers, including enantiomers, may be separated using techniques standard in the art; however, racemic mixtures or mixtures containing more than one diastereomer may also be used. The compounds as indicated in formulas 1-4, therefore, are  
10 representative of the individual optical isomers, enantiomers or diasteriomers as the case may be, as well as mixtures of these individual chiral isomers.


If desired, the compounds of the invention can be prepared in metallated forms by treating the tetrapyrrole-type nucleus with an appropriate ion such as magnesium ion, zinc ion, stannous ion and the like, to obtain a metal complex. The metal ion may  
15 also be a radiolabel. Generally, the metal ion is inserted using the appropriate salts under conditions standard in the art. For example, zinc ion can be introduced by treating the compound with zinc acetate in 1:1 methylene chloride:methanol.

The compounds may also contain label, including radioisotopes, chromophores, and fluorescent labels. Radioisotope labeling is generally useful when  
20 the compounds are to be followed *in vivo* or used to label specific moieties. Useful cationic moieties that are radioisotopes include technetium, gallium and indium. In addition, radioisotopes of heteroatoms, such as <sup>131</sup>I or <sup>32</sup>P, in the molecule itself, or inclusion of <sup>14</sup>C may be used to label the molecule.


As further described in the BPD-related patents set forth above, the  
25 compounds of the invention may be coupled, if desired, to a targeting agent which will direct the molecule to a specific tissue or organ. Such targeting agents include antibodies, receptors, receptor-ligands and the like. Linkage of the targeting agent to the compound is conducted using standard techniques. By a "conjugated form" is meant a compound of formulas 1-4 coupled to a targeting agent, as above described.

30 Preferred embodiments of the compounds of formulas 1-4 include those wherein both n equal 2, or those wherein both R<sup>1</sup> are ethyl or methyl, preferably

methyl, and those wherein R<sup>2</sup> is vinyl. Particularly preferred are compounds of the formula



and



Both A-EA6 and B-EA6 have been prepared. Both are effective  
5 photosensitizers; it appears that A-EA6 is the easier to formulate.

The various forms of the compounds of the invention can be used in the photodynamic therapy techniques generally known in the art. As set forth in the Background section above, photodynamic therapy can be conducted using a plethora of protocols and for a variety of indications. In addition, compounds of this type  
10 exhibit pharmacological activity in the absence of light in some instances. Standard pharmaceutical compositions, including liposomal compositions as preferred, are used as desired in such applications.

The following examples are intended to illustrate but not to limit the invention. While the Examples illustrate and demonstrate the surprising  
15 pharmacokinetic properties of two members of the species of the invention, A-EA6 and B-EA6, it is expected that the remaining compounds described by formulas 1-4 will have similar variations in these properties. Hence, the small class of compounds contained in the present invention offers valuable additions to the repertoire of photodynamic agents useful in treating the various conditions to which this therapy  
20 has been directed.

Example 1Preparation of Two Forms of EA6

A. To prepare B-EA6, the starting material is BPD-DB as the dimethyl ester -- i.e., BPD-DB as shown in Figure 1 wherein R<sup>1</sup> and R<sup>2</sup> are both COOMe and R<sup>3</sup> is vinyl.

To 2.0 g (2.7 mM) BPD-DB in 50 mL ethylene glycol and 100 mL dichloromethane was added 1.0 mL sulfuric acid. The reaction was stirred for 18 hr. at room temperature. Then the reaction was added to a stirring mixture of 100 mL 5% aqueous ammonium acetate and 100 mL dichloromethane. The organic layer was isolated and then washed twice with 50 mL water. The solvent was removed by rotary evaporation. The dark green residue was then chromatographed on 75 g alumina (deactivated with 5% water) and eluted with a gradient of 0.5%-5.0% methanol in dichloromethane. The solvent from the fractions containing product was then removed by rotary evaporation. The residue was dried *in vacuo* overnight to provide 2.02 g (89%) of the analytically pure green solid title compound.

B. In a manner similar to that set forth in paragraph A, but substituting BPD-DA for BPD-DB, the isomeric form, A-EA6 was prepared.

Example 2Comparison of Uptake and Release of B-EA6 and BPD-MA by L1210 Cells

BPD-MA or B-EA6 were incubated at 3 µg/ml in the presence of 10% fetal bovine serum with 10<sup>7</sup>/mL of L1210 cells, a murine leukemia cell line. Intracellular content of the photosensitizers was measured by fluorescence of cell lysates at various times. The maximum concentration reached was 145.9 ng/10<sup>6</sup> cells for B-EA6 and 149.5 ng/10<sup>6</sup> cells for BPD-MA. The time course of uptake is shown in Figure 2 as a percentage of cell content at 60 min by which time uptake had reached a maximum in both cases. As shown, B-EA6 is taken up more rapidly and reaches 80% of its maximum concentration after only 5 min and reached its maximum uptake within 15 min.

The kinetics of release of these drugs from L1210 cells was measured by preloading the cells at 3 µg/ml for 1 hr and then placing the cells in drug-free medium

containing 10% fetal bovine serum. Remaining intracellular drug content was measured at various time points by lysing the cells and measuring fluorescence. As shown in Figure 3 (again as a percent of starting intracellular content), BPD-MA and B-EA6 showed different kinetics of release. Initial release of B-EA6 was much more rapid, but release was more complete in the case of BPD-MA.

It was unexpected that the *in vitro* pharmacokinetics of B-EA6 were more rapid than those of BPD-MA. While the higher retention of B-EA6 could be attributed to its increased size as compared to BPD-MA, the faster transfer through the cellular membrane was unexpected.

10

### Example 3

#### Comparison of *In Vivo* Pharmacokinetics

Either BPD-MA or B-EA6 was administered by intravenous injection into DBA/2 mice at a dose of 4 mg/kg using 3 mice per time point. The drug content of plasma, skin, liver and kidney was determined by fluorescence in the tissue extracts. Figure 4 shows the results plotted as a percentage of the concentration in the relevant tissue 15 min postinjection. As seen in Figure 4, neither BPD-MA nor B-EA6 accumulated in plasma, liver or kidney; however, BPD-MA accumulated in skin within the first 3 hr; B-EA6 does not.

20 The more rapid accumulation of B-EA6 as compared to BPD-MA, as here confirmed *in vivo* by more rapid clearance from all tissues, constitutes an advantage. The treatment with light can be carried out soon after injection of the photosensitizer and due to the rapid clearance, no prolonged skin or eye photosensitivity will be exhibited. Thus, the subjects treated can resume normal lives without special  
25 precautions such as avoiding bright light and wearing dark eyeglasses.

The half-life of B-EA6 and BPD-MA in various tissues was then computed in the time-frame 15 min-3 hr and the results are shown in Table 1:

- 10 -

**Table 1: Tissue Half-Lives of B-EA6 and BPD-MA**

Tissue	T½ * (15 min-3 hours)	
	B-EA6	BPD-MA
Liver	0.6	2.4
Spleen	0.8	10.9
Kidney	0.8	5.6
Skin	1.9	0**
Muscle	11.1	ND†
Plasma	0.6	2.0

\* shown in hours

\*\* BPD-MA concentration in the skin increased for up to 3 hr

† ND = not determined

5        The half-life of BPD-MA in this time-frame could not be computed in skin since its concentration increased during the 3 hr period. As shown in Table 1, generally, B-EA6 has a much shorter half-life than BPD-MA in most tissues. The lack of accumulation of B-EA6 in normal skin as compared to BPD-MA was unexpected, and indicates more rapid clearance than that of BPD-MA. As set forth  
 10 above, this is advantageous as skin photosensitivity is the only recognized side effect of photodynamic therapy utilizing photosensitizers.

15      The pharmacokinetics were also determined using an *in vivo* mouse tumor model. Groups of 10 DBA/2 mice containing M1 rhabdomyosarcoma tumors were injected intravenously with a liposomal formulation of BPD-MA at various dosages of 0.75-1.5 mg/kg. The tumors were irradiated with 690 nm laser light at 50 or 150 J/cm<sup>2</sup> at various times after injection. The results, as shown in Table 2, were determined in terms of the percentage of mice in each group that were tumor-free on day 7 after injection.

**Table 2: Results of Bioassay**

PDT Conditions			Percent Tumor Free on Day 7*	
Drug**	Time post IV (min)	Light*** dose (J/cm <sup>2</sup> )	BPD-MA	B-EA6
0.75	15	50	(4/5)	50%
	30	50	70%	0%
1.0	15	50	100%	90%
	30	50	90%	0%
1.5	180	150	70%	0%

\* tumor model = MI tumor in DBA/2 mice - each PDT condition was tested in 10 animals

\*\* the drugs were liposomally formulated and injected intravenously

\*\*\* 690 nm laser light.

5

As shown in Table 2, BPD-MA treated mice showed substantial survival rates when postinjection times ranged from 15-180 min. On the other hand, B-EA6 treated mice showed no response at 30 min or 180 min; however, significant responses were obtained when irradiation was supplied after only 15 min.

10

These data demonstrate that PDT using B-EA6 will be effective in early treatment with light. The lack of effect of later times postinjection indicates, again, rapid clearance of B-EA6 which is advantageous for the reasons set forth above.

15

#### Determination of LD<sub>50</sub> With and Without Serum

Either B-EA6 or BPD-MA was incubated for 1 hr with L1210 cells at a range of concentrations and exposed to 9 J/cm<sup>2</sup> broad spectrum light. This determination was made in the absence of serum and in the presence of 10% serum. The results are shown in Table 3.

20

**Table 3: LD<sub>50</sub> Values**

	No serum	10% serum
BPD-MA	3.7 ng/ml	54.0 ng/ml
B-EA6	4.7 ng/ml	19.7 ng/ml

As shown, BPD-MA and B-EA6 have comparable LD<sub>50</sub> values in the absence of serum; however, in the presence of serum, B-EA6 shows a substantially better retention of effectiveness.

- In most instances, the presence of serum greatly reduces the photoactivity of agents used in PDT, such as BPD-MA. Surprisingly, B-EA6 shows more affinity for cell membranes than for plasma components and is thus very slightly affected by the presence of serum in the cellular environment. Thus, *in vivo*, its activity may be
- 5 higher than that of BPD-MA and other compounds of this family.

Example 5

In Vitro Efficacy of B-EA6

The ability of B-EA6 to exert a cytotoxic effect on L1210 cells *in vitro* was

10 further tested by incubating the cells with B-EA6 at various concentrations for 1 hr in the absence of serum. After excess drug was removed, the cells were exposed to 9 J/cm<sup>2</sup> broad spectrum light (380-750 nm) and cell survival was determined by the MTT assay (Mosmann, T. *et al. J Immunol Meth* (1983) 65:55-63). The percentage of killed cells was calculated in reference to survival of cells exposed to light only. At a

15 concentration of approximately 7 ng/ml, 80% of the cells were killed; at 15 ng/ml, almost 100% of the cells did not survive. As stated above, the LD<sub>50</sub> for B-EA6 is approximately 4.7 ng/ml.

The somewhat lower effect of B-EA6 as compared to BPD-MA *in vitro* makes even more unexpected the comparatively higher activity of B-EA6 as compared to

20 BPD-MA *in vivo* in the presence of serum as demonstrated in Example 4.

Example 6

Selectivity of B-EA6 for Tumor Cells

The ability of L1210 cells to accumulate B-EA6 was compared to the ability

25 of splenocytes to do so. B-EA6 at 3 µg/ml was incubated with each cell type and the cell content of B-EA6 was determined by fluorescence in cell lysates. Figure 5 shows a comparison of uptake for the two cell types in ng/10<sup>6</sup> cells. As shown, L1210 cells were able to take up approximately 140 ng/10<sup>6</sup> cells reaching this value after approximately 20 min. Splenocytes, on the other hand, accumulated less than

30 20 ng/10<sup>6</sup> cells after an hour of incubation.

- 13 -

DBA/2 mice bearing M1 (rhabdomyosarcoma) tumor, grown subcutaneously in their flanks, were used as a model to show that B-EA6 demonstrated selectivity for tumors. Mice were administered 0.75 mg/kg of B-EA6 in a liposomal formulation intravenously. After 15 min, a 1 cm area which included a 5 mm diameter tumor was 5 exposed to 50 J/cm<sup>2</sup> of 70 mW light of 690 nm wavelength from an argon-pumped dye laser. The exposure effectively eliminated the tumor, but did not affect the surrounding normal skin. Thus, B-EA6 demonstrates tumor specificity.

Example 7

10

Immunomodulation by B-EA6

Balb/C mice (5-8 mice per group) were tested using the delayed skin photosensitivity assay also called the contact hypersensitivity (CHS) assay. The mice were painted in the flank with the sensitizing agent dinitrofluorobenzene (DNFB) and 5 days later, one ear is challenged with DNFB, while the other serves as a control. 15 The swelling is an indicator of immune response. Mice were injected intravenously with 1 mg/kg liposomal B-EA6 and either irradiated with 15 J/cm<sup>2</sup> light over the whole body or exposed to ambient light. The ability of this treatment to prevent the immune response as demonstrated by inhibition of ear swelling was determined. The results showed that administering B-EA6 combined with either after irradiation with 20 15 J/cm<sup>2</sup> whole body light or with ambient light decreased swelling in the test ear as compared to untreated mice. The swelling in both cases was only approximately 60% of the that shown in mice without treatment.

In an additional assay to determine immunomodulation, murine peritoneal macrophages were isolated, purified and activated by recombinant interferon- $\gamma$  25 (100 U/ml). The activated cells were incubated for 1 hr at 37°C with B-EA6 at a range of concentrations and then exposed to 690 nm LED light at 5 J/cm<sup>2</sup>. Expression levels of MHC I, MHC II, CD54, CD80 and CD86 were determined 24 hr later using FITC conjugated antibodies and a cell sorter. The results are shown in Table 4 for B-EA6 at 0.5 ng/ml in comparison to similar experiments using BPD-MA at 30 2.5 ng/ml.

**Tabl 4: Effect of Low-Dose PDT with B-EA6 on Expression Levels of Cell Surface Antigens by Murine Peritoneal Macrophages**

Compound	MHC Class I	MHC Class II	CD54 (ICAM-1)	CD80 (B7-1)	CD86 (B7-2)
BPD-MA (2.5 ng/ml)	99.1 ± 4.3%	79.3 ± 10.1%	105.4 ± 3.0%	93.5%	99.2%
BPD-B-EA6 (0.5 ng/ml)	100.4%	71.8%	106.9%	102.3%	92.2%

The results in the table are given as a percent of expression as compared to cells treated with light only. As shown, BPD-MA and B-EA6 were both able to reduce expression of MHC II, but not the remaining surface markers. Thus, although 5 B-EA6 has advantageous pharmacokinetics, it retains the immunomodulatory activity of BPD-MA and other compounds of this group.

#### Example 8

##### Effect of B-EA6 in an Arthritis Model

10 MRL-Ipr mice spontaneously develop arthritis; this was enhanced by intradermal injection of Freund's Adjuvant. Various numbers of MRL-Ipr mice were treated with PDT on days 0, 10, and 20 after injection of the adjuvant. PDT consisted of 0.5 mg/kg liposomal B-EA6 injected intravenously followed by exposure of the ventral part of the mice to red (560-900 nm) light at 80 J/cm<sup>2</sup> at 1 hr post-B-EA6 15 injection. The mice were observed and symptoms scored every 5 days for 30 days. The results are shown in Figure 6 in comparison to mice similarly treated with BPD-MA and BPD-MB. As shown in Figure 6, whether measured by the incidence of clinical symptoms (i.e., the percentage of mice exhibiting these symptoms) or by the change in bimaleolar ankle width in millimeters, B-EA6 (shown as solid circles) 20 was effective in preventing the sequelae of adjuvant injection.

Again, the retention of immunomodulatory activity of B-EA6 is demonstrated.

#### Example 9

##### Effect of B-EA6 on Microvasculature

25 The mouse cremaster muscle model was used. B-EA6 was administered intravenously at 2 mg/kg and starting at 5 and 15 min postinjection, surgically

- 15 -

exposed arterioles and venules were irradiated with light at an intensity of 25 J/cm<sup>2</sup> per 5 min beginning at 5 min and 15 min after injection of the B-EA6. The vessels were measured as red blood column diameter as a percentage of controls.

The results are shown in Figure 7. While transient vessel closure could be  
5 obtained when irradiation was started at 5 min, permanent closure was obtained when radiation was started after 15 min.

The enhanced capacity of B-EA6 to constrict or occlude vasculature, as demonstrated in this Example, in combination with more rapid pharmacokinetics, make B-EA6 particularly advantageous in treating neovascular diseases in the eye.

10

#### Example 10

##### Absorption Spectrum of B-EA6

BPD-MA and B-EA6 have similar absorption spectra in plasma before and after 4-hr exposure to fluorescent (380-750 nm) light. A comparison of these spectra  
15 is shown in Figure 8. The similarity of the spectrum of B-EA6 to the spectrum of BPD-MA is advantageous since the use of BPD-MA as a therapeutic agent useful in PDT is well developed. The similarity in their spectra indicates that the same light sources can be used for B-EA6 as are successful in treatment with BPD-MA.

20

#### Example 11

##### In Vitro Cytotoxicity of A-EA6

In a manner similar to that set forth in Example 5, the cytotoxicity of A-EA6  
*in vitro* on two different cell lines was tested and compared with BPD-MA. Either  
25 L1210 cells or the dendritic cell line D2SC/1 was incubated for one hour at 37°C with either A-EA6 or BPD-MA. After removal of excess drug, the cells were exposed to 690 nm light at 5 J/cm<sup>2</sup> light for dendritic cells and at 9°J/cm<sup>2</sup> light for L1210 cells. Cell survival was determined 18-24 hours later using the MTT colorimetric assay described in Example 5. Percent cells killed was calculated by reference to cells exposed to light only. As shown in Figure 9A, A-EA6 showed comparable  
30 cytotoxicity to BPD-MA with respect to L1210 cells in the absence of serum but was markedly more toxic in the presence of serum than BPD-MA. The open circles

- 16 -

represent A-EA6 plus serum; the closed circles represent BPD-MA plus serum; open squares represent A-EA6 in the absence of serum; and closed squares represent BPD-MA in the absence of serum.

As shown in Figure 9B, in dendritic cells where BPD-MA has an LD<sub>50</sub> of 5 ng/ml and A-EA6 has an LD<sub>50</sub> of 2.7 ng/ml, A-EA6 was toxic at lower concentrations than BPD-MA in the presence of 5% fetal calf serum. In Figure 9B, closed circles represent BPD-MA and open squares represent A-EA6.

In a similar determination, but measuring MHC I receptors rather than cytotoxicity, A-EA6 was effective in decreasing expression of these receptors at lower 10 concentrations. In this determination, dendritic cells were incubated for 1 hour at a drug concentration less than its LD<sub>50</sub>; 2.5 ng/ml and 5 ng/ml for BPD-MA and 1 ng/ml and 2.5 ng/ml for A-EA6. The cells were treated with 690 nm light at 5 J/cm<sup>2</sup> and then labeled with the appropriate antibody 3 hours post-treatment and assessed by flow cytometry. The results were measured as the percent of the mean channel 15 fluorescence intensity for light-treated control cells. These results are shown in Figure 10; BPD-MA gave an 18% and a 29% reduction, respectively, at 2.5 ng/ml and 5 ng/ml; A-EA6 lowered the channel fluorescence by approximately 25% at both 1 ng/ml and 2.5 ng/ml concentrations.

20

### Example 12

#### Effect of A-EA6 on Intracellular Signaling

The conditions of the study set forth in Example 11 were repeated using 25 HL-60 cells as the target and comparing the effects of A-EA6 and BPD-MA on cytotoxicity, on the mitogenic pathway kinase p70 S6K, and on the stress pathway kinases c-jun and HSP27. The results are shown in Figure 11. At sublethal concentrations, A-EA6 showed stronger activation of the stress pathway kinases and stronger inhibition of the mitogenic pathway kinases.

The effect on caspase activation in HL-60 cells was also measured. A-EA6 showed a stronger activation of caspases than did BPD-MA. This effect is desirable 30 as it is associated with apoptosis. Using apoptosis to remove unwanted cells causes

the least effect on surrounding normal cells and tissues. The comparison of A-EA6 with BPD-MA is shown in Figure 12.

Figure 13 shows a similar comparison when percent DNA fragmentation was measured in HL-60 cells. Again, A-EA6 was effective at lower concentrations than  
5 BPD-MA.

Example 13

In Vivo Photodynamic Therapy Using A-EA6

In a protocol similar to that set forth in Example 3, either A-EA6 or BPD-MA  
10 was injected intravenously into mice harboring M1 tumors at a dose of 1 mg/kg. This was followed by whole body irradiation with 50 J/cm<sup>2</sup> of 690 nm laser light at various times after administration of the drug. The number of tumor-free animals on day 7 was determined and the results are shown in Table 5.

**Table 5**

Photosensitizer	Irradiation time (post i.v.)	Day 7 tumor-free animals
BPD-MA	15 min	10/10
	30 min	9/10
A-EA6	15 min	2/2
	30 min	6/6

15 These results show A-EA6 is at least as effective as BPD-MA in this assay.

Example 14

Immunomodulatory Activity

Flanks of control and test mice were painted with the antigen DMFB and their  
20 ears were challenged 5 days later by pasting with the same compound. Test animals were treated with whole-body PDT using BPD-MA or A-EA6, by injecting the photosensitizer intravenously and then exposing the animals to red LED light at 15 J/cm<sup>2</sup>. The percent suppression of ear swelling was calculated in comparison to controls. The results are shown in Table 6 and indicate that A-EA6 had a stronger  
25 immunomodulatory effect in this assay than did BPD-MA.



- 18 -

**Table 6**

Phot sensitizer	Dose (mg/kg)	Percent suppression
BPD-MA	1.0	49%
A-EA6	1.0	68%
A-EA6	0.3	59%

Claims

## 1. A compound of the formula



5

and the metallated and/or labeled and/or conjugated forms thereof

wherein each R<sup>1</sup> is independently alkyl (1-6C);

each n is independently an integer of 0-6; and

R<sup>2</sup> is vinyl or a derivative form thereof.

10

2. The compound of claim 1 wherein R<sup>2</sup> is vinyl, -CHOR', -CHO,  
 -COOR', -CH(OR')CH<sub>3</sub>, -CH(OR')CH<sub>2</sub>OR', -CH(SR')CH<sub>3</sub>, -CH(NR')<sub>2</sub>CH<sub>3</sub>,  
 -CH(CN)CH<sub>3</sub>, -CH(COOR')CH<sub>3</sub>, -CH(OOCR')CH<sub>3</sub>, -CH(NR'COR')CH<sub>3</sub>,  
 -CH(CONR')CH<sub>3</sub>, -CH(halo)CH<sub>3</sub>, or -CH(halo)CH<sub>2</sub>(halo) wherein R' is H, or a  
 hydrocarbon radical (1-6C) optionally substituted with a heteroatom substituent or

- 20 -

wherein R<sup>2</sup> is an organic group of less than 12C resulting from direct or indirect derivatization of a vinyl substituent, or  
 wherein R<sup>2</sup> is a group containing 1-3 tetrapyrrole-type nuclei.


5        3.     The compound of claim 1 or 2 which is in a metallated form, and/or which is in conjugated form, and/or which is labeled.

4.     The compound of claim 1 or 2 which does not contain a metal ion.


10      5.     The compound of any of claims 1-4 wherein R<sup>2</sup> is vinyl, and/or wherein each R<sup>1</sup> is methyl, and/or wherein both n are 2.

6.     The compound of claim 5 wherein R<sup>2</sup> is vinyl and both R<sup>1</sup> are methyl.

15      7.     The compound of claim 6 which is of the formula



and



and the metallated and/or labeled and/or conjugated forms thereof.

20      8.     The compound of claim 7 which is in a metallated form, and/or which is in conjugated form, and/or which is labeled.

- 21 -


9. The compound of claim 7 which does not contain a metal ion.

10. A pharmaceutical composition which comprises the compound of any of claims 1-9 in admixture with at least one pharmaceutically acceptable excipient.


5

11. An improved method to conduct photodynamic therapy or diagnosis wherein said method comprises administering a photoactive compound to a subject in need of said therapy or diagnosis wherein the improvement comprises use of the compound of any of claims 1-9 as the photoactive agent.


10




BPD-DA



BPD-DB



BPD-MA



BPD-MB

FIG. 1

2 / 13




FIG. 2




FIG. 3

3 / 13




FIG. 4A




FIG. 4B

4 / 13




FIG. 4C





FIG. 4D

5 / 13

**FIG. 5**

6 / 13




FIG. 6A








FIG. 6B

**FIG. 7A****FIG. 7B**

8 / 13

**FIG. 8A****FIG. 8B**

9 / 13




FIG. 9A

10 / 13





FIG. 9B

11 / 13

**FIG. 10**

STRESS PATHWAY KINASES




FIG. 11A

MITOGENIC PATHWAY KINASES




FIG. 11B

CYTOTOXICITY MTT ASSAYS




FIG. 11C

13 / 13




FIG. 12




FIG. 13

# INTERNATIONAL SEARCH REPORT

Inte ional Application No  
PCT/CA 98/00468

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 C07D487/22 A61K51/00 A61K41/00 A61K51/04 A61K51/10  
//(C07D487/22,257:00,209:00,209:00,209:00,209:00)

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 352 076 A (THE UNIVERSITY OF BRITISH COLUMBIA) 24 January 1990 cited in the application see claims 1,8 ---	1,9
A	WO 90 15059 A (THE UNIVERSITY OF BRITISH COLUMBIA) 13 December 1990 see claims 1,11 ---	1,9
A	US 5 498 710 A (R. K. PANDEY ET AL) 12 March 1996 see column 3 - column 4; claims 1-4 -----	1,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
17 August 1998	26/08/1998
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  Voyiazoglou, D

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 98/00468

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 11 because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim 11 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.